Irene Ekwede

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

Jung‐Min Lee, Jayakumar R. Nair, Alexandra S. Zimmer et al. · The Lancet Oncology · 2018 · 210 citations · Full text

Medicine, Gynecology, Pathology +6

Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases

Ramya Ramaswami, Kathryn Lurain, Mark N. Polizzotto et al. · Blood Advances · 2021 · 68 citations · Full text

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma

Kathryn Lurain, Ramya Ramaswami, Ralph Mangusan et al. · Journal for ImmunoTherapy of Cancer · 2021 · 56 citations · Full text

Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404).

Jung‐Min Lee, Alexandra Dos Santos Zimmer, Stan Lipkowitz et al. · Journal of Clinical Oncology · 2016 · 31 citations

Parp Inhibitor, Immunology, Recurrent Ovarian Cancer +16

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

Daniel S. Green, Ana T. Nunes, Virginia David‐Ocampo et al. · Journal of Translational Medicine · 2018 · 29 citations · Full text